TransMedics Group Inc. (TMDX)
88.35
2.97 (3.48%)
At close: Apr 17, 2025, 3:59 PM
3.48% (1D)
| Bid | 83.5 |
| Market Cap | 2.97B |
| Revenue (ttm) | 441.54M |
| Net Income (ttm) | 35.46M |
| EPS (ttm) | 1.07 |
| PE Ratio (ttm) | 82.57 |
| Forward PE | 39.27 |
| Analyst | Buy |
| Ask | 88.79 |
| Volume | 887,464 |
| Avg. Volume (20D) | 1,349,395.8 |
| Open | 85.89 |
| Previous Close | 85.38 |
| Day's Range | 84.53 - 88.39 |
| 52-Week Range | 55.00 - 177.37 |
| Beta | 2.13 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. I...
Industry Medical - Devices
Sector Healthcare
IPO Date May 2, 2019
Employees 728
Stock Exchange NASDAQ
Ticker Symbol TMDX
Website https://www.transmedics.com
Analyst Forecast
According to 11 analyst ratings, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is $112, which is an increase of 26.77% from the latest price.
Stock ForecastsNext Earnings Release
TransMedics Group Inc. is scheduled to release its earnings on Apr 29, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+5.82%
TransMedics Group shares are trading higher after ...
Unlock content with
Pro Subscription
1 month ago
-2.22%
TransMedics Group shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 revenue guidance above estimates.
